Myriad Genetics Acquires Counsyl, a Women’s Health Lab

Myriad Genetics Acquires Counsyl, a Women’s Health Lab

by | May 31, 2018 11:37 am | Laboratories, MRI & Dialysis, Private Equity | 0 comments

Myriad Genetics (NASDAQ: MYGN) agreed to pay $375 million to acquire privately held Counsyl, Inc., which operates a high-complexity clinical laboratory dedicated to women’s health. Counsyl’s lab services include carrier and non-invasive prenatal screening, including its Foresight Carrier Screen, Prelude Prenatal Screen, Reliant Cancer Screen, as well as supporting services through Counsyl Complete, a suite of solutions that integrate Counsyl screening into clinical workflows and patients’ lives. Since the company’s founding, Counsyl has championed key advances in screening for women and their families, screening more than 850,000 patients, serving more than 17,000... Read More »

Myriad Genetics Eyes GeneSight

by | Aug 18, 2016 7:04 pm | Pharmaceuticals | 0 comments

Myriad Genetics Inc. (NASDAQ: MYGN), which specializes in molecular diagnostics and personalized medicine, started off August with the acquisition of privately-held Assurex Health Inc., an informatics-based, personalized medicine company that specializes in pharmacogenomics, a study of the genetic factors that influence an individual’s response to drug treatments, for behavioral health and chronic pain conditions. Assurex was sold for an upfront payment of $225 million, and is also eligible to receive up to $185 million in additional performance-based milestones. The acquisition gives Myriad access to GeneSight®, one of the fasting growing diagnostic tests in a multi-billion dollar market.... Read More »